Rezafungin and invasive candida infections: a new game changing antifungal?
- PMID: 36442483
- DOI: 10.1016/S0140-6736(22)02371-6
Rezafungin and invasive candida infections: a new game changing antifungal?
Conflict of interest statement
I hold a permanent researcher position at Fundación para Investigación Sanitaria del Hospital Gregorio Marañón. I report research grants from Basilea, Gilead, Scynexis, Cidara, F2G, and Mundipharma and personal fees from Pfizer, Mundipharma, Gilead, and MSD, outside the submitted work.
Comment on
-
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442484 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
